Topical Therapy in Psoriasis: Clinical Benefits, Advances in Novel Drug Delivery Strategies, and Gene Therapy Regimen

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 283 - 283

Published: Feb. 20, 2025

Psoriasis is a chronic inflammatory disease with complex pathogenesis, influenced by various factors involving environment, genes, and immunity. The main symptoms of psoriasis include erythema, scales, itching, etc. At present, therapeutic drugs for are continually evolving towards enhancing treatment efficacy reducing side effects. Firstly, the pathogenesis characteristics were summarized. Then, types benefits topical therapy introduced, such as aspects avoiding systemic toxic effects, first pass effect, gastrointestinal reactions accelerating onset time improving its efficacy, compared to drugs. In case methotrexate, cyclosporin A, Janus kinase (JAK) inhibitors, phosphodiesterase-4 (PDE-4) this review had further discussion on improvement translation these molecules from in clinical practice. To augment limitation skin permeability, nanotechnology novel drug delivery system including nanomedicines, hydrogels, ionic liquids, microneedles elaborated management. Also, exploration targeting pathogenic genes through small interfering RNA (siRNA) using nanoparticles liquids (ILs) great significance long-term psoriasis. Taken together, development numerous platforms expected achieve enhanced penetration, precise efficient molecule interference (RNAi) therapeutics prospects.

Language: Английский

---

Novel Small-Molecule Treatment and Emerging Biological Therapy for Psoriasis

Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 781 - 781

Published: March 23, 2025

Psoriasis is an immune-related disorder that marked by abnormal thickening of the skin, rapid multiplication keratinocytes, and complex interactions between immune cells affected areas. Although psoriasis cannot currently be cured, drugs can alleviate symptoms regulating homeostasis preventing comorbidities. There are many types to treat psoriasis: small-molecule drugs, including corticosteroids; retinoids; vitamin D analogs; immunosuppressants, such as glucocorticoid ointment, tretinoin cream, methotrexate tablets, etc. Macromolecular biological Certolizumab, Secukinumab, Guselkumab, etc., include monoclonal antibodies target various inflammatory signaling pathways. Compared with traditional therapies offer better targeting lower systemic side effects, but their high costs invasive administration modes constrict widespread use. Spesolimab latest agent used interleukin-36 receptor (IL-36R) approved for market use, which significantly reduces risk general pustular (GPP) flare 84%. Additionally, there several agents interleukin-23/T helper 17 cell pathway have already entered Phase II III clinical trials. At present, first-line therapeutic strategy mild topical administration. Systemic therapy phototherapy preferred treating moderate severe types. However, current completely meet needs. More advanced drug delivery systems optimized effects bioavailability required. Nanocarriers emerging proteins, nucleic acids, cell-based therapies. In this review, we analyze status therapeutics discuss novel diverse well We also summarize effectiveness different strategies.

Language: Английский

---

Hybrid membrane-coated Cyclosporine A nanocrystals preventing secondary brain injury via alleviating neuroinflammatory and oxidative stress

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: unknown, P. 113795 - 113795

Published: April 1, 2025

Language: Английский

---

Enhanced transdermal delivery of insulin by choline-based ionic liquids

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: unknown, P. 125006 - 125006

Published: Nov. 1, 2024

Language: Английский

---